Alan Bash

Bio:

Alan Bash joined Legend Biotech in October 2024 and serves as the President of CARVYKTI®.

Mr. Bash has over 20 years of strategic and operational leadership experience across multiple therapeutic areas, disciplines, product lifecycles, and geographies. In his role, he oversees the commercial, technical operations, and quality functions of the CARVYKTI franchise.

Prior to Legend, Mr. Bash was the Chief Executive Officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as President and CEO at Checkmate Pharmaceuticals. Before that, he also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas – including oncology – driving the U.S.  launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux®. Mr. Bash contributed to several blockbuster products in collaboration with other companies, including Abilify with Otsuka and Eliquis® with Pfizer.

Mr. Bash earned his MBA from Columbia Business School and his BA in political science from Georgetown University.